Exelixis (EXEL) Net Cash Flow (2010 - 2026)
Exelixis (EXEL) recorded quarterly Net Cash Flow of -$256.3 million in Q2 2026, down 341.4% quarter-over-quarter from $106.2 million in Q1 2026, and down 662.41% on a YoY basis from $45.6 million in Q2 2025.
Exelixis (EXEL) Net Cash Flow (2010 - 2026) Analysis & Trends
Exelixis' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$256.3 million for Q2 2026.
- In Q2 2026, Net Cash Flow fell 662.41% year-over-year to -$256.3 million; the TTM figure through Apr 2026 stood at $42.4 million (up 155.93% YoY), while the FY2026 annual figure was $265.1 million, up 681.14% from the prior year.
- Net Cash Flow was -$256.3 million for Q2 2026 at Exelixis, down from $106.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $211.9 million in Q4 2025 to a low of -$256.3 million in Q2 2026.
- Historically, Net Cash Flow has averaged -$25.7 million across 5 years, with a median of -$33.6 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow sank 879.38% in 2025, then jumped 359.17% in 2026.
- A 5-year view of Net Cash Flow shows it stood at -$174.1 million in 2022, then increased by 23.11% to -$133.9 million in 2023, then surged by 144.74% to $59.9 million in 2024, then jumped by 253.78% to $211.9 million in 2025, then sank by 220.99% to -$256.3 million in 2026.
- The last three Net Cash Flow figures came in at -$256.3 million (Q2 2026), $106.2 million (Q1 2026), and $211.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 664,983.53 |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | -256.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -256.34 Mn |
| Apr 3, 2026 | -256.34 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Dec 29, 2023 | -133.87 Mn |
| Dec 29, 2023 | -133.87 Mn |